摘要
目的观察和评价白蛋白结合型紫杉醇(Nab-P)治疗吉西他滨一线化疗失败后晚期胰腺癌的疗效和安全性。方法回顾分析2012年5月至2015年5月接受Nab-P单药或联合方案(Nab-P 110 mg/m^2静滴,第1、8天,21天为1周期)作为二线或二线以上治疗的晚期胰腺癌患者。分别采用RECIST 1.1版与NCI-CTC 4.0版标准评价近期疗效和毒副反应。采用Kaplan-Meier法进行生存分析。结果共纳入13例患者,其中9例可评价疗效和毒副反应。9例患者平均年龄为56.1岁,Nab-P平均治疗2.27个周期。9例患者的疾病控制率(DCR)为55.6%,其中2例获PR,3例SD,4例PD;CA199较基线下降50%者4例(44.4%);中位疾病进展时间(TTP)为3.3个月(95%CI:2.4~4.2个月),中位生存时间(OS)为14.2个月(95%CI:2.8~25.6个月);3个月及6个月生存率分为88.9%和77.8%。常见毒副反应多为1~2级,主要为白细胞减少、中性粒细胞减少、乏力、恶心、呕吐等。结论 Nab-P对国人吉西他滨一线治疗失败后的晚期胰腺癌具有较好的疗效,且耐受性良好。
Objective To evaluate the efficacy and safety of Nab-paclitaxel( Nab-P) on patients with advanced pancreatic carcinoma who failed to gemcitabine first-line therapy. Methods Patients with advanced pancreatic carcinoma who have failed to firstline therapy from May 2012 to May 2015 were analyzed retrospectively. All the patients received Nab-P-based monotherapy or combination regimens( Nab-P 110 mg / m^2 iv,d1,d8,every 3 weeks) as second or more line treatments. The efficacy and safety were evaluated by RECIST 1. 1 and NCI-CTC 4. 0 criteria. Median time to disease progression( TTP) and overall survival( OS) were analyzed by Kaplan-Meier method. Results Thirteen patients failured to gemcitabine-based regimen were enrolled and 9 of them were evaluatable.The median age was 56. 1 years,and the average treatment cycle was 2. 27. The disease control rate( DCR) was 55. 6%,including 2cases of PR,3 cases of SD and 4 cases of PD. The number of patients with elevated baseline CA19-9 had 50% decline was 4( 44. 4%). The median TTP was 3. 0 months( 95% CI: 2. 4-4. 2 months) and the median OS was 14. 2 months( 95% CI: 2. 8-25. 6months). The 3-month and 6-month survival rate was 88. 9% and 77. 8%,respectively. The major treatment-related side effects including leucopenia,neutropenia,nausea,vomiting,fatigue and etc. were mainly in grade 1-2. Conclusion Nab-paclitaxe is effective and tolerable in Chinese advanced pancreatic carcinoma patients who have progressed on gemcitabine first-line therapy.
出处
《临床肿瘤学杂志》
CAS
2015年第10期913-917,共5页
Chinese Clinical Oncology